Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Niraparib First-line Maintenance Therapy In Patients With Newly Diagnosed Advanced Ovarian Cancer: Final Overall Survival Results From The Prima/engot-ov26/gog-3012 Trial

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial

B J Monk1, M P Barretina-Ginesta2, B Pothuri3

  • 1GOG Foundation, Philadelphia; Florida Cancer Specialists and Research Institute, West Palm Beach, USA.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|September 16, 2024

Related Experiment Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.6K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.4K

View abstract on PubMed

Summary
This summary is machine-generated.

Niraparib maintenance therapy did not improve overall survival in advanced ovarian cancer patients. However, it showed a trend towards longer progression-free survival, especially in the homologous recombination-deficient subgroup.

Keywords:
PARP inhibitormaintenanceniraparibovarian cancer

Related Experiment Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.6K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.4K

Area of Science:

  • Gynecologic Oncology
  • Clinical Pharmacology
  • Medical Statistics

Background:

  • The PRIMA/ENGOT-OV26/GOG-3012 trial investigated niraparib as first-line maintenance therapy for newly diagnosed advanced ovarian cancer.
  • Niraparib demonstrated significant progression-free survival (PFS) benefits, irrespective of homologous recombination deficiency (HRD) status, in patients responding to platinum-based chemotherapy.

Purpose of the Study:

  • To report the final overall survival (OS) results from the phase III PRIMA/ENGOT-OV26/GOG-3012 trial.
  • To evaluate the long-term efficacy and safety of niraparib maintenance therapy in advanced ovarian cancer.

Main Methods:

  • Randomized, double-blind, placebo-controlled trial with a 2:1 allocation to niraparib or placebo.
  • Stratification based on response to chemotherapy, neoadjuvant treatment, and HRD status.
  • OS was analyzed hierarchically using a stratified log-rank test, with an updated PFS analysis.

Main Results:

  • No significant difference in OS was observed between niraparib and placebo in the overall population (HR 1.01) or HRD subgroups.
  • A numerical trend favoring niraparib was noted for 5-year PFS rates in both overall (22% vs 12%) and HRD (35% vs 16%) populations.
  • Long-term safety profile of niraparib remained consistent, with low incidence of myelodysplastic syndromes/acute myeloid leukemia.

Conclusions:

  • Niraparib maintenance therapy did not significantly improve overall survival in patients with newly diagnosed advanced ovarian cancer.
  • In the HRD subgroup, patients receiving niraparib were twice as likely to be progression-free at 5 years compared to placebo.
  • Long-term safety data support the established safety profile of niraparib.
overall survival